GlobeNewswire: Crinetics Pharmaceuticals, Inc. Contains the last 10 of 151 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:24:22ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848371/0/en/Crinetics-Once-Daily-Oral-Paltusotine-Achieved-the-Primary-and-All-Secondary-Endpoints-in-the-Phase-3-PATHFNDR-2-Study-in-Acromegaly-Patients.html?f=22&fvtc=4&fvtv=35881Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients2024-03-19T10:00:00Z<![CDATA[56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001)]]>https://www.globenewswire.com/news-release/2024/03/12/2845006/0/en/Crinetics-Announces-Positive-Topline-Results-from-Phase-2-Trial-of-Paltusotine-for-the-Treatment-of-Carcinoid-Syndrome.html?f=22&fvtc=4&fvtv=35881Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome2024-03-12T20:05:00Z<![CDATA[Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements]]>https://www.globenewswire.com/news-release/2024/03/11/2844146/0/en/Crinetics-Pharmaceuticals-Announces-March-2024-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=35881Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-03-11T20:05:00Z<![CDATA[SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/28/2837423/0/en/Crinetics-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=35881Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update2024-02-28T21:05:00Z<![CDATA[Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024]]>https://www.globenewswire.com/news-release/2024/02/28/2836890/0/en/Crinetics-Pharmaceuticals-Announces-Oversubscribed-350-Million-Private-Placement.html?f=22&fvtc=4&fvtv=35881Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement2024-02-28T13:00:00Z<![CDATA[SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement. Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses. The private placement is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/02/14/2829439/0/en/Crinetics-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-28-2024.html?f=22&fvtc=4&fvtv=35881Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 20242024-02-14T21:05:00Z<![CDATA[SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a business update.]]>https://www.globenewswire.com/news-release/2024/02/12/2827855/0/en/Crinetics-Pharmaceuticals-Announces-February-2024-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=35881Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-02-12T21:05:00Z<![CDATA[SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/01/10/2807531/0/en/Crinetics-Pharmaceuticals-Announces-January-2024-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=35881Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-01-10T21:33:42Z<![CDATA[SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/01/03/2803244/0/en/Crinetics-Pharmaceuticals-to-Participate-in-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=35881Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T13:00:00Z<![CDATA[SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024.]]>https://www.globenewswire.com/news-release/2023/12/18/2798132/0/en/Crinetics-Announces-Positive-Initial-Findings-from-Ongoing-Open-Label-Phase-2-Study-of-Paltusotine-for-the-Treatment-of-Carcinoid-Syndrome.html?f=22&fvtc=4&fvtv=35881Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome2023-12-18T21:05:00Z<![CDATA[Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed]]>